As of November 6, 2026, Korro Bio, Inc. is a publicly traded company (Nasdaq: KRRO). The largest holder reporting an active stake on Schedule 13D is New Enterprise Associates 17, L.P., at 9.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, March 12, 2026).
Is this your company?
About to sign with, pay or invest in Korro Bio, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Korro Bio, Inc. a real, registered company?
- Korro Bio, Inc. files with the SEC under CIK 1703647 (its SEC filings).
- Its shares are listed under the ticker KRRO on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Cambridge, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Korro Bio, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2025-11-12).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Balyasny Asset Management L.P. (filed 2026-08-14).
Who are Korro Bio, Inc.'s owners and officers?
Korro Bio, Inc.: incorporated in Delaware; business address in Cambridge, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-27 | Blackrock, Inc. | 4.9% |
| Schedule 13G/A, 2026-08-14 | Balyasny Asset Management L.P. | 6.6% |
| Schedule 13D/A, 2026-08-04 | Atlas Venture Fund Xi, L.P. | 4.9% |
| Schedule 13G, 2026-07-29 | Blackrock, Inc. | 5.2% |
| Schedule 13G/A, 2026-05-15 | Point72 Biotech Private Investments, LLC | 1.9% |
| Schedule 13G/A, 2026-04-02 | Lynx1 Capital Management LP | 10.7% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G, 2026-03-17 | Venrock Healthcare Capital Partners Iii, L.P. | 9.9% |
| Schedule 13D/A, 2026-03-12 | New Enterprise Associates 17, L.P. | 9.9% |
| Schedule 13G, 2026-03-11 | Steven A. Cohen | 5.7% |
| Schedule 13G/A, 2026-02-17 | Driehaus Capital Management LLC | 0% |
| Schedule 13G/A, 2026-02-17 | Point72 Biotech Private Investments, LLC | 2.9% |
Questions about who owns Korro Bio, Inc.
Who owns Korro Bio, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Korro Bio, Inc.: Lynx1 Capital Management LP (10.7%, Schedule 13G/A, filed 2026-04-02), Venrock Healthcare Capital Partners Iii, L.P. (9.9%, Schedule 13G, filed 2026-03-17), New Enterprise Associates 17, L.P. (9.9%, Schedule 13D/A, filed 2026-03-12), Balyasny Asset Management L.P. (6.6%, Schedule 13G/A, filed 2026-08-14) and Steven A. Cohen (5.7%, Schedule 13G, filed 2026-03-11).
Who are the largest shareholders of Korro Bio, Inc.?
By the share each holder's latest filing reports, the largest holders of Korro Bio, Inc. on this page are Lynx1 Capital Management LP (10.7%), Venrock Healthcare Capital Partners Iii, L.P. (9.9%) and New Enterprise Associates 17, L.P. (9.9%).
When did Lynx1 Capital Management LP buy into Korro Bio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lynx1 Capital Management LP on this page is the Schedule 13G/A, filed 2026-04-02, reporting 10.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Korro Bio, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Korro Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Korro Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Korro Bio, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 1,624,789 shares (11.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-10-26).
- Lynx1 Capital Management LP, a 10% owner: 1,624,789 shares (11.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-10-26).
- , a 10% owner: 1,297,893 shares (9.5% of shares outstanding), held indirectly through a see note 2 (Form 4, 2026-03-12).
- , a 10% owner: 1,297,893 shares (9.5% of shares outstanding), held indirectly through a see note 2 (Form 4, 2026-03-12).
- , a 10% owner: 1,297,893 shares (9.5% of shares outstanding), held indirectly through a see note 2 (Form 4, 2026-03-12).
Shares outstanding: 13,725,646 as of 2026-11-03, from the company's latest SEC cover page.
How much has Korro Bio, Inc. raised?
No fundraising or offering filing from Korro Bio, Inc. is on file with us.
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2025-11-12).
Keep reading
More on Korro Bio, Inc. and the records around it.
Korro Bio, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Layoff notices Nov 2025
Companies that share a holder
- Atlas Venture Fund XI, L.P. also filed stake reports on 3 other companies: DYNE THERAPEUTICS, INC. (Aug 2026), Day One Biopharmaceuticals, Inc. (May 2026), SIONNA THERAPEUTICS, INC. (Oct 2025)
- New Enterprise Associates 17, L.P. also filed stake reports on 4 other companies: Monte Rosa Therapeutics, Inc. (Jul 2026), Inventiva S.A. (Apr 2026), SpyGlass Pharma, Inc. (Feb 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/korro-bio